|
|
What are the possible side effects of RAPAFLO®?
Well tolerated. Safety profile proven in medical studies.
The most common side effect with RAPAFLO is orgasm with reduced or no semen. This is an expected side effect of alpha-blockers
that target the prostate, and is not harmful to your health. This effect is not permanent, and is reversible
once you stop taking RAPAFLO. RAPAFLO does not affect a man's ability to achieve orgasm
or to have and maintain an erection.
Although the amount of semen may be different, sex can still be pleasurable.
Other less common side effects associated with RAPAFLO include dizziness, diarrhea,
lightheadedness upon standing or sitting up abruptly, headache, swelling of the
throat and nasal passages, and stuffy nose.
Like all alpha-blockers, RAPAFLO might cause a slight drop in blood pressure, especially
when you stand up quickly after sitting or lying down. This may make you dizzy or
lightheaded, especially if you are already have low blood pressure or are taking
medications for high blood pressure. You should not drive, operate machinery, or
do any dangerous activities until you know how RAPAFLO affects you.
RAPAFLO does not affect a man's ability to achieve orgasm or to have and maintain
an erection.
- Fenter TC, Naslund MJ, Shah MB, et al. The cost of treating the 10 most prevalent diseases in men 50 years of age or older. Am J Manag Care. 2006;12(4 suppl):S90-S98
- Data on file, Watson Pharma, Inc.
- National Institute of Diabetes and Digestive and Kidney Diseases. Prostate enlargement: benign prostatic hyperplasia. NIH Publication No. 07-3012. June 2006.
- Bruskewitz RC. Quality of life and sexual function in patients with benign prostatic hyperplasia. Rev Urol. 2003;5(2):72-80
- Roberts RO, Jacobsen SJ, Rhodes T, et al. Natural history of prostatism: impaired health status in men with lower urinary tract symptoms. J Urol. 1997;157:1711-1717
- RAPAFLO™ (silodosin) full prescribing information. Corona, CA: Watson Pharma Inc. October 2008.
- Agency for Healthcare Quality and Research (U.S. Dept Health and Human Services): Quick Tips When Talking With Your Doctor. Available at: http://www.ahrq.gov/consumer/quicktips/doctalk.htm.
- American Urological Association. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol. 2003;170:530-547
- Nickel JC. Comparison of clinical trials with finasteride and dutasteride. Rev Urol. 2004;6 Suppl 9:S31-9
- Benign Prostatic Hyperplasia (BPH): A Patient’s Guide. Available at: http://www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines/patient-guides/bph_guide_2003.pdf. Accessed February 4, 2009.
- National Institute on Aging: Talking With Your Doctor. Available at: http://www.nia.nih.gov/HealthInformation/Publications/TalkingWithYourDoctor/. Accessed March 5, 2009.
- Medline Plus Medical Encyclopedia from NIH: Enlarged Prostate. Available at: http://www.nlm.nih.gov/medlineplus/ency/article/000381.htm. Accessed March 5, 2009.
- Shvartzman P, Borkan JM, Stoliar L, et al. Second-hand prostatism: effects of prostatic symptoms on spouses’ quality of life, daily routines and family relationships. Family Pract. 2001;18:610-613.
- Kuritzky L. A primary care physician’s perspective on benign prostatic hyperplasia. Rev Urol. 2003;5(suppl 5):S42-S48.
- Wolters R, et al: Lower urinary tract symptoms: social influence is more important than symptoms in seeking medical care. BJU Int. 2002;90:655–661.
- Rosen RC, Giuliano F, Cason CC. Sexual dysfunction and lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Eur Urol 2005;47:824–837.
- Ponholzer A, Madersbacher S. Lower urinary tract symptoms and erectile dysfunction; Links for diagnosis, management and treatment. Int J Impot Res. 2007;19:544-550.
- Straus SM, Kors JA, De Bruin ML, et al. Prolonged QTc interval and risk of sudden cardiac death in a population of older adults. J Am Coll Cardiol. 2006;47:362-367.
- Nomiya M, Yamaguchi O. A quantitative analysis of mRNA expression of alpha 1 and beta-adrenoceptor subtypes and their functional roles in human normal and obstructed bladders. J Urol. 2003;170(2 Pt 1):649-653.
- Murata S, Taniguchi T, Takahashi M, et al. Tissue selectivity of KMD-3213, an alpha(1)-adrenoreceptor antagonist, in human prostate and vasculature. J Urol. 2000;164:578-583.
- Stafford-Smith M, Bartz R, Wilson K, et al. Alpha-adrenergic mRNA subtype expression in the human nasal turbinate. Can J Anesth. 2007;54:549-555.
- Cialis® (tadalafil) full Prescribing Information. Indianapolis IN: Eli Lilly and Co.; June 2007.
- Viagra® (sildenafil) full Prescribing Information. New York, NY: Pfizer Inc. October 2006.
- Levitra® (vardenafil) full Prescribing Information. Kenilworth, NJ: Schering Corporation.
- McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;18:2387-2398
- Issa MM, Regan T. Medical therapy for benign prostatic hyperplasia—present and future impact. Am J Manag Care. 2007;13:S4-S9.
- Wei JT, Calhoun E, Jacobsen SJ. Urologic Diseases in America Project: benign prostatic hyperplasia. J Urol. 2008;179(5 Suppl.):S75-S80.
- Berry SJ, Coffey DS, Walsh PC, et al. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132:474.
- Hernández C, Estivill E, Prieto M, et al. Nocturia in Spanish patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH). Curr Med Res Opin. 2008;24(4):1033-1038
- Schwinn DA, Roehrborn CG alpha-1 Adrenoreceptor subtypes and lower urinary tract symptoms. Int J Urol. 2008; 15:193-199.
- http://www.dictionary.com
- Atlas of Human Anatomy, Frank H. Netter, MD, Ciba-Geigy Corporation, Summit, NJ, 1989.
|